PetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery Conference

Rhea-AI Summary

PetVivo Holdings (OTCQX:PETV) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata, Atlantic City.

CEO John Lai will deliver a company presentation and hold one-on-one investor meetings. The presentation will cover lead products Spryng (intra-articular ECM microparticle device with OsteoCushion technology) and PrecisePRP (off-the-shelf allogeneic, leucoreduced, freeze-dried PRP: 4 billion platelets per vial; 500,000 platelets/µL; 1500 WBC/µL). Investors may request a complimentary investor pass and contact info1@petvivo.com or visit petvivoanimalhealth.com and sprynghealth.com for more information.

News Market Reaction – PETV

-5.08%

1 alert

-5.08% News Effect

On the day this news was published, PETV declined 5.08%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Platelets per vial: 4 billion platelets Platelet concentration: 500,000 platelets per microliter White blood cells: Less than 1500 per microliter +2 more

5 metrics

Platelets per vial 4 billion platelets Each PrecisePRP vial dose

Platelet concentration 500,000 platelets per microliter PrecisePRP intra-articular administration

White blood cells Less than 1500 per microliter Leucoreduced PrecisePRP formulation

Conference dates January 28–29, 2026 3rd Annual DealFlow Discovery Conference

Conference edition 3rd Annual DealFlow Discovery Conference

Market Reality Check

Price: $0.7400 Vol: Volume 28,176 vs 20-day a...

normal vol

$0.7400 Last Close

Volume Volume 28,176 vs 20-day average 20,847 (relative volume 1.35x) ahead of the conference update. normal

Technical Shares at $1.18 are trading above the $0.88 200-day MA and about 30% below the 52-week high of $1.69.

Peers on Argus

Healthcare/medical device peers are mixed: one notable gainer PYNKF at +17.14%, ...

Healthcare/medical device peers are mixed: one notable gainer PYNKF at +17.14%, while others like GTHP at -11.76% and BTCY at -1.35% are down. PETV’s modest +1.72% move appears more stock-specific than a broad sector trend.

Historical Context

5 past events · Latest: Dec 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 16	AI explainer launch	Positive	-2.5%	Video explainer showcasing PetVivo.ai ecosystem and 10 specialized AI agents.
Nov 25	AI platform launch	Positive	-14.1%	PetVivo AI SaaS launch after beta with disclosed CAC, pricing and margins.
Nov 25	AI platform launch	Positive	-14.1%	PetVivo.ai launch highlighting CAC reductions, ARR projections and economics.
Nov 17	AI framework paper	Positive	-9.8%	Technical whitepaper validating AgenticPet AI Framework under 10-year license.
Nov 14	Earnings update	Positive	-9.8%	Fiscal Q2 2026 results with 51% revenue growth and 72.6% gross margin.

Pattern Detected

Recent news—AI launches and revenue growth—was generally positive in tone, yet the stock showed negative 24-hour reactions after each of the last five announcements.

Recent Company History

Over the past months, PetVivo reported several milestones, including an AI platform launch with strong unit economics on Nov 25, 2025 and fiscal Q2 2026 results on Nov 14, 2025 showing 51% revenue growth to $303,000 and 72.6% gross margin. Despite these seemingly constructive updates, 24-hour price reactions ranged from about -2.5% to -14%. Today’s conference participation and product-focused communication fit into this pattern of frequent operational updates to the market.

Market Pulse Summary

The stock moved -5.1% in the session following this news. A negative reaction despite neutral-to-pos...

Analysis

The stock moved -5.1% in the session following this news. A negative reaction despite neutral-to-positive product visibility news fits a recent pattern where constructive announcements, including AI launches and revenue growth, were followed by 24-hour drops such as -9.77% and -14.06%. The conference participation mainly reiterates product attributes rather than adding new financial data, so traders may have discounted its impact. Historically, similar communication-focused updates have not prevented short-term downside volatility.

Key Terms

intra-articular, extra-cellular matrix, synovial lining, platelet-rich plasma, +3 more

7 terms

intra-articular medical

"Spryng is an intra-articular injectable veterinary medical device"

An intra-articular treatment is one that is injected directly into a joint space, such as the knee or shoulder, to deliver medication or therapy right where the problem is. For investors, this matters because intra-articular delivery can improve effectiveness and reduce systemic side effects compared with pills or injections elsewhere in the body, affecting a drug’s clinical value, regulatory pathway, market appeal, and reimbursement prospects.

extra-cellular matrix medical

"composed of sterilized, extra-cellular matrix microparticles"

A network of proteins and sugars that surrounds and supports cells, acting like a scaffolding and glue that holds tissues together and helps cells talk to each other. Investors care because the extracellular matrix affects how diseases progress, how well drugs and implants work, and whether therapies meet safety and regulatory standards—making it a key factor in market value, clinical success, and product development in healthcare and biotech.

synovial lining medical

"adsorb onto the joint synovial lining of animals"

The synovial lining is the thin membrane that lines joint cavities and produces the slippery fluid that lets bones glide smoothly against each other—think of it as the inner coating of a hinge or balloon that reduces friction. It matters to investors because damage or inflammation of this lining is a key driver of joint diseases, treatment success, regulatory decisions and market demand for drugs, devices and diagnostics aimed at easing pain or restoring function.

platelet-rich plasma medical

"PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product"

Platelet-rich plasma is a concentrated portion of a person’s own blood where platelets — the small cells that help blood clot and encourage tissue repair — are collected and returned to an injured area to speed healing. For investors, PRP is important because it creates demand for clinic services, medical devices and consumable kits; how well treatments work, regulatory clearance, and how widely clinicians adopt them can directly affect revenue potential, like selling a specialized repair kit to hospitals and clinics.

allogeneic medical

"a leucoreduced, allogeneic, pooled, freeze-dried PRP"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

freeze-dried medical

"allogeneic, pooled, freeze-dried PRP intended to provide"

Freeze-dried describes a preservation process that removes almost all water from a product by freezing it and then gently turning the ice into vapor under low pressure, like drying fruit without using heat. For investors, freeze-drying matters because it greatly extends shelf life, preserves potency and quality (important for drugs, vaccines and specialty foods), and lowers storage and shipping risks and costs, supporting commercial scalability and regulatory compliance.

leucoreduced medical

"PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP"

Leucoreduced describes blood products that have had most white blood cells removed before transfusion, like running water through a fine filter to take out tiny particles. For investors, this matters because removing white cells lowers the risk of fever, allergic reactions and some immune complications, which can shape demand for safer blood products, affect production costs, and influence regulatory approval and hospital purchasing decisions.

AI-generated analysis. Not financial advice.

MINNEAPOLIS, MN / ACCESS Newswire / December 23, 2025 / PetVivo Holdings, Inc. (OTCQX:PETV)(OTCID:PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about PetVivo Holdings, Inc. and its innovative products at www.petvivo.com.

In the presentation Mr. Lai will be providing information about its lead products, Spryng® with OsteoCushion® Technology and PrecisePRP™. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.

Event Details:

• 3rd Annual DealFlow Discovery Conference

• The Borgata Hotel, Casino & Spa

• Atlantic City, NJ

• January 28-29, 2026

Investors interested in scheduling a meeting with the [Company Name] management team should request an investor pass to attend the conference (no cost to attend). For more information about Spryng and PrecisePRP, please contact info1@petvivo.com or visit petvivoanimalhealth.com and sprynghealth.com.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW),in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

Company Contact

John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking commercial Statements

The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: PetVivo Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

When will PetVivo (PETV) present at the DealFlow Discovery Conference?

PetVivo will present on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City.

Who from PetVivo (PETV) will speak and meet investors at the conference?

CEO John Lai will deliver the company presentation and be available for one-on-one investor meetings.

What product details will PetVivo (PETV) present about Spryng?

Spryng is an intra-articular ECM microparticle device using OsteoCushion technology intended to integrate with subsynovial tissue and aid joint pain management.

What are the key specifications of PetVivo's PrecisePRP (PETV)?

PrecisePRP is an off-the-shelf allogeneic freeze-dried PRP with 4 billion platelets per vial, 500,000 platelets/µL, and <1500 WBC/µL.

How can investors schedule a meeting with PetVivo (PETV) management at DealFlow?

Investors should request a complimentary investor pass and contact info1@petvivo.com for scheduling details.